Effects of Naproxen on Physical Performance

This study has been terminated.

(Study never initiated.)

Sponsor:

Information provided by:

University of Oklahoma

ClinicalTrials.gov Identifier:

NCT00410995

First received: December 12, 2006

Last updated: October 10, 2007

Last verified: October 2007

History of Changes

Tracking Information

First Received Date ^ICMJE

December 12, 2006

Last Updated Date

October 10, 2007

Start Date ^ICMJE

May 2004

Primary Completion Date

Not Provided

Current Primary Outcome Measures ^ICMJE

Effects on physical performance in terms of maximum oxygen consumption

Original Primary Outcome Measures ^ICMJE

Same as current

Change History

Complete list of historical versions of study NCT00410995 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Not Provided

Original Secondary Outcome Measures ^ICMJE

Not Provided

Current Other Outcome Measures ^ICMJE

Not Provided

Original Other Outcome Measures ^ICMJE

Not Provided

Descriptive Information

Brief Title ^ICMJE

Effects of Naproxen on Physical Performance

Official Title ^ICMJE

Effects of Naproxen on Physical Performance

Brief Summary

The purpose of this study is to determine the effect of daily use of Naproxen (a commonly used over-the-counter NSAID) on the physical performance of athletes, as measured by maximum oxygen consumption.

Detailed Description

Not Provided

Study Type ^ICMJE

Interventional

Study Phase

Phase 4

Study Design ^ICMJE

Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Condition ^ICMJE

Healthy

Intervention ^ICMJE

Drug: Naproxen

Study Arm (s)

Not Provided

Publications *

Not Provided

* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Terminated

Enrollment ^ICMJE

Completion Date

August 2006

Primary Completion Date

Not Provided

Eligibility Criteria ^ICMJE

Inclusion Criteria:

Age equal to or greater than18 years of age
No history of allergy or adverse reaction to any NSAID
No use of any NSAID in past 2 weeks
No history of peptic ulcer disease (PUD), gastroesophageal disease (GERD), or gastritis
No major medical history including but not limited to diabetes, hypertension, asthma, kidney disease and coronary artery disease
Currently not taking any medication including oral contraceptives

Exclusion Criteria:

Age < 18 years of age
History of allergy or adverse reaction to any NSAID
Use of any NSAID in past 2 weeks
History of a bleeding disorder
History of PUD, GERD, or gastritis
Pregnant
A medical history of diabetes, hypertension, asthma, kidney disease or coronary artery disease
Taking any medication including oral contraceptives

Gender

Both

Ages

18 Years to 30 Years

Accepts Healthy Volunteers

Yes

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

United States

Administrative Information

NCT Number ^ICMJE

NCT00410995

Other Study ID Numbers ^ICMJE

11186

Has Data Monitoring Committee

Not Provided

Responsible Party

Not Provided

Study Sponsor ^ICMJE

University of Oklahoma

Collaborators ^ICMJE

Not Provided

Investigators ^ICMJE

Principal Investigator:

LaMont Cavanagh, MD

University of Oklahoma-Tulsa

Information Provided By

University of Oklahoma

Verification Date

October 2007

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top